Correct me if this is wrong, but hasn't this type of off-label use for tPA been around for a long time, as long ago as 2001. It seems like the drug companies are just looking for more off-label use for drugs they already have. I would suggest if a drug company did similar studies on the effect of aspirin on catheter occlusion, they may find beneficial effects as well.
http://www.factsandcomparisons.com/assets/hospitalpharm/Off1.pdfhttp://medical-dictionary.thefreedictionary.com/Activasealteplase (tissue plasminogen activator, recombinant) Warning - High-alert drug!
Actilyse (UK), Activase, Activase rt-PA (CA), Cathflo Activase, Lysatec rt-PA (CA)
Pharmacologic class: Plasminogen activator
Therapeutic class: Thrombolytic
Adverse reactions
CNS: cerebral hemorrhage, cerebral edema, CVA (with accelerated infusion)
CV: hypotension, bradycardia, recurrent ischemia, pericardial effusion, pericarditis , mitral regurgitation, electromechanical dissociation, arrhythmias, cardiogenic shock, heart failure, cardiac arrest, cardiac tamponade, myocardial rupture, embolization, venous thrombosis
GI: nausea, vomiting, GI bleeding
GU: GU tract bleeding
Hematologic: spontaneous bleeding, bone marrow depression
Musculoskeletal: musculoskeletal pain
Respiratory: pulmonary edema
Skin: bruising, flushing
Other: fever, edema, phlebitis or bleeding at I.V. site, hypersensitivity reaction (including rash, anaphylactic reaction, laryngeal edema ), sepsis
Interactions
Drug-drug. Aspirin, drugs affecting platelet activity (such as abciximab, heparin, dipyridamole, oral anticoagulants, vitamin K antagonists): increased risk of bleeding
Drug-diagnostic tests. Blood urea nitrogen: elevated level
Patient monitoring
• Monitor vital signs, ECG, and neurologic status.
• Maintain strict bed rest.
• Watch for signs and symptoms of bleeding tendency and hemorrhage.
• Monitor patient on Cathflo Activase for GI bleeding, venous thrombosis, and sepsis.
• Evaluate results of clotting studies.